Plasmid profile of representative clinical isolates and transconjugants.

<p>1. <i>E. coli</i> 50192 (154-, 68-, and 36-kb), 2. pUA21 (275 kb), 3. 835, 4. T835, 5. 836, 6. T836, 7. 837, 8. T837, 9. 839, 10. T839, 11. 840, 12. T840, 13. 843, 14. T843, 15. T850, 16. 850, 17. 6737, 18. T6737, 19. 844. </p

Demographic and clinical characteristics in patients with EC-ESBL and controls.

*<p>SD: Standard deviation.</p

Molecular characterization of Escherichia coli ESBL.

<p>Molecular characterization of extended-spectrum beta-lactamase <i>Escherichia coli</i> producers (n = 56).</p

Clinical characteristics in patients with EC-ESBL and controls.

*<p>BMT = Bone marrow transplantation.</p

Antimicrobials used in Escherichia coli ESBL and in the control group.

<p>Antimicrobials used during the previous month in extended-spectrum beta-lactamase <i>Escherichia coli</i> and the <i>E.coli</i> control group.</p

Mean survival (days) and outcome according appropriate antimicrobial treatment^*.

*<p>Appropriate antimicrobial treatment was considered when this had been initiated within the first 48 h of first symptoms and if the patient had received this for at least >72 h, including an antibiotic with susceptibility for the isolated <i>E. coli</i> strain.</p

Kaplan Meier survival curve for Escherichia coli ESBL and control patients according to antimicrobial treatment.

<p>Kaplan-Meier survival curve for patients with extended-spectrum beta-lactamase <i>Escherichia coli</i> and the <i>E. coli</i> control group, stratified according to appropriate vs. non-appropriate antimicrobial treatment.</p

<i>Escherichia coli</i>-ESBL isolated from 2004 to 2009.

<p>Total number of <i>Escherichia coli</i> extended-spectrum beta-lactamases (ESBL) isolated from blood cultures at Instituto Nacional de Cancerología, Mexico City (2004–2009).</p